Dermatology Drugs Market Competitive Landscape:

Different dermatological medications manufactured by key players are being endorsed by the administrative specialists, for example, the U.S. Food and Drug Administration (USFDA) and the European Union (EU), which, thus, is decidedly influencing the development of the dermatology drugs showcase. For example, in November 2018, the USFDA allowed the need audit for Sanofi's supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as potential treatment for immature patients (matured 12– 17 years) with uncontrolled moderate-to-extreme atopic dermatitis.

Essentially, in September 2018, Sanofi got the USFDA endorsement for its Libtayo (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or privately progressed CSCC who are not possibility for corrective medical procedure or healing radiation.

A portion of the other key players working in the worldwide dermatology drugs industry are Celgene Corporation, Bausch Health Companies Inc., Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Johnson and Johnson, Allergan plc, Merck and Co. Inc., Amgen Inc., AbbVie Inc., Eli Lilly and Company, Nestlé Skin Health S.A., GlaxoSmithKline plc, Mylan N.V., and LEO Pharma A/S.

contact us : derma@meetingsint.com